Pyrazinamide Resistance and Mutation Patterns Among Multidrug-Resistant Mycobacterium tuberculosis from Henan Province

References

• Diacon AH, Van Baelen B, Theeuwes M. More on treatment outcomes in multidrug-resistant tuberculosis. N Engl J Med. 2016;375(26):2609–2610.
   Google Scholar
• Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009;4(9):e6914. doi:10.1371/journal.pone.000691419742330
   PubMed Web of Science ®Google Scholar
• Collaborative Group for the Meta-Analysis of Individual Patient Data in MDRTBt, Ahmad N, Ahuja SD, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821–834. doi:10.1016/S0140-6736(18)31644-1.30215381
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xu S, Wang L, et al. National survey of drug-resistant tuberculosis in China. N Engl J Med. 2012;366(23):2161–2170. doi:10.1056/NEJMoa110878922670902
   PubMed Web of Science ®Google Scholar
• Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010;375(9728):1830–1843. doi:10.1016/S0140-6736(10)60410-220488523
   PubMed Web of Science ®Google Scholar
• Dheda K, Chang KC, Guglielmetti L, et al. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Microbiol Infect. 2017;23(3):131–140. doi:10.1016/j.cmi.2016.10.00827756712
   PubMed Web of Science ®Google Scholar
• Scorpio A, Lindholm-Levy P, Heifets L, et al. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1997;41(3):540–543. doi:10.1128/AAC.41.3.5409055989
   PubMed Web of Science ®Google Scholar
• Zhang Y, Shi W, Zhang W, Mitchison D. Mechanisms of pyrazinamide action and resistance. Microbiol Spect. 2014;2(4):MGM2-0023-2013. doi:10.1128/microbiolspec.MGM2-0023-2013
   Google Scholar
• Mestdagh M, Fonteyne PA, Realini L, et al. Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1999;43(9):2317–2319. doi:10.1128/AAC.43.9.231710471589
   PubMed Web of Science ®Google Scholar
• Stoffels K, Mathys V, Fauville-Dufaux M, Wintjens R, Bifani P. Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2012;56(10):5186–5193. doi:10.1128/AAC.05385-1122825123
   PubMed Web of Science ®Google Scholar
• Zhang S, Chen J, Shi W, Liu W, Zhang W, Zhang Y. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect. 2013;2(6):e34. doi:10.1038/emi.2013.3826038471
   PubMed Web of Science ®Google Scholar
• Huy NQ, Lucie C, Hoa TTT, et al. Molecular analysis of pyrazinamide resistance in Mycobacterium tuberculosis in Vietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolates. Emerg Microbes Infect. 2017;6(10):e86. doi:10.1038/emi.2017.7329018250
   PubMed Web of Science ®Google Scholar
• Shi W, Zhang X, Jiang X, et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science. 2011;333(6049):1630–1632. doi:10.1126/science.120881321835980
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chiu Chang K, Leung CC, et al. ‘Z(S)-MDR-TB’ versus ‘Z(R)-MDR-TB’: improving treatment of MDR-TB by identifying pyrazinamide susceptibility. Emerg Microbes Infect. 2012;1(7):e5. doi:10.1038/emi.2012.1826038418
   PubMed Web of Science ®Google Scholar
• Tam KK, Leung KS, Siu GK, et al. Direct detection of pyrazinamide resistance in mycobacterium tuberculosis by use of pncA PCR sequencing. J Clin Microbiol. 2019;57:8. doi:10.1128/JCM.00145-19
   Web of Science ®Google Scholar
• Kurbatova EV, Cavanaugh JS, Dalton T, Click ES, Cegielski JP. Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009. Clin Infect Dis. 2013;57(8):1081–1093. doi:10.1093/cid/cit45223840002
   PubMed Web of Science ®Google Scholar
• Shi J, Zheng D, Zhu Y, et al. Role of MIRU-VNTR and spoligotyping in assessing the genetic diversity of Mycobacterium tuberculosis in Henan Province, China. BMC Infect Dis. 2018;18(1):447. doi:10.1186/s12879-018-3351-y30176820
   PubMed Web of Science ®Google Scholar
• Kamerbeek J, Schouls L, Kolk A, et al. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J Clin Microbiol. 1997;35(4):907–914. doi:10.1128/JCM.35.4.907-914.19979157152
   PubMed Web of Science ®Google Scholar
• Chen YY, Chang JR, Wu CD, et al. Combining molecular typing and spatial pattern analysis to identify areas of high tuberculosis transmission in a moderate-incidence county in Taiwan. Sci Rep. 2017;7(1):5394. doi:10.1038/s41598-017-05674-628710410
   PubMed Web of Science ®Google Scholar
• Mokrousov I, Ly HM, Otten T, et al. Origin and primary dispersal of the Mycobacterium tuberculosis Beijing genotype: clues from human phylogeography. Genome Res. 2005;15(10):1357–1364. doi:10.1101/gr.384060516169923
   PubMed Web of Science ®Google Scholar
• Dookie N, Rambaran S, Padayatchi N, Mahomed S, Naidoo K. Evolution of drug resistance in Mycobacterium tuberculosis: a review on the molecular determinants of resistance and implications for personalized care. J Antimicrob Chemother. 2018;73(5):1138–1151. doi:10.1093/jac/dkx50629360989
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015. Int J Tuberculosis Lung Dis. 2015;19(11):1276–1289. doi:10.5588/ijtld.15.0389
   Web of Science ®Google Scholar
• Pang Y, Zhu D, Zheng H, et al. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. BMC Infect Dis. 2017;17(1):711. doi:10.1186/s12879-017-2761-629110640
   PubMed Web of Science ®Google Scholar
• Gu Y, Yu X, Jiang G, et al. Pyrazinamide resistance among multidrug-resistant tuberculosis clinical isolates in a national referral center of China and its correlations with pncA, rpsA, and panD gene mutations. Diagn Microbiol Infect Dis. 2016;84(3):207–211. doi:10.1016/j.diagmicrobio.2015.10.01726775806
   PubMed Web of Science ®Google Scholar
• Xu P, Wu J, Yang C, et al. Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China. Tuberculosis. 2016;98:56–61. doi:10.1016/j.tube.2016.02.00827156619
   PubMed Web of Science ®Google Scholar
• Liu W, Chen J, Shen Y, et al. Phenotypic and genotypic characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Hangzhou, China. Clin Microbiol Infect. 2018;24(9):1016e1011–1016 e1015. doi:10.1016/j.cmi.2017.12.012
   Web of Science ®Google Scholar
• Gopal P, Gruber G, Dartois V, Dick T. Pharmacological and molecular mechanisms behind the sterilizing activity of pyrazinamide. Trends Pharmacol Sci. 2019;40(12):930–940. doi:10.1016/j.tips.2019.10.00531704175
   PubMed Web of Science ®Google Scholar
• Alame-Emane AK, Xu P, Pierre-Audigier C, et al. Pyrazinamide resistance in Mycobacterium tuberculosis arises after rifampicin and fluoroquinolone resistance. Int J Tuberculosis Lung Dis. 2015;19(6):679–684. doi:10.5588/ijtld.14.0768
   Web of Science ®Google Scholar
• Zignol M, Dean AS, Alikhanova N, et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis. 2016;16(10):1185–1192. doi:10.1016/S1473-3099(16)30190-627397590
   PubMed Web of Science ®Google Scholar
• Zignol M, Floyd K. Resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones - authors’ reply. Lancet Infect Dis. 2017;17(1):25. doi:10.1016/S1473-3099(16)30538-227998569
   PubMed Web of Science ®Google Scholar
• Budzik JM, Jarlsberg LG, Higashi J, et al. Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California. PLoS One. 2014;9(4):e95645. doi:10.1371/journal.pone.009564524759760
   PubMed Web of Science ®Google Scholar
• Suzuki S, Horinouchi T, Furusawa C. Prediction of antibiotic resistance by gene expression profiles. Nat Commun. 2014;5:5792. doi:10.1038/ncomms679225517437
   PubMed Web of Science ®Google Scholar
• Raju S, Ye CJ. How mutations express themselves in blood-cell production. Nature. 2019;571(7765):329–330. doi:10.1038/d41586-019-02028-231308526
   PubMed Web of Science ®Google Scholar
• Bhuju S, Fonseca Lde S, Marsico AG, et al. Mycobacterium tuberculosis isolates from Rio de Janeiro reveal unusually low correlation between pyrazinamide resistance and mutations in the pncA gene. Infect Genetics Evol. 2013;19:1–6. doi:10.1016/j.meegid.2013.06.00823770140
   PubMed Web of Science ®Google Scholar
• Doustdar F, Khosravi AD, Farnia P. Mycobacterium tuberculosis genotypic diversity in pyrazinamide-resistant isolates of Iran. Microb Drug Resist. 2009;15(4):251–256. doi:10.1089/mdr.2009.006619857130
   PubMed Web of Science ®Google Scholar
• Jonmalung J, Prammananan T, Leechawengwongs M, Chaiprasert A. Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand. BMC Microbiol. 2010;10:223. doi:10.1186/1471-2180-10-22320727143
   PubMed Web of Science ®Google Scholar
• Jureen P, Werngren J, Toro JC, Hoffner S. Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2008;52(5):1852–1854. doi:10.1128/AAC.00110-0818316515
   PubMed Web of Science ®Google Scholar
• Whitfield MG, Soeters HM, Warren RM, et al. A global perspective on pyrazinamide resistance: systematic review and meta-analysis. PLoS One. 2015;10(7):e0133869. doi:10.1371/journal.pone.013386926218737
   PubMed Web of Science ®Google Scholar
• Li D, Hu Y, Werngren J, et al. Multicenter study of the emergence and genetic characteristics of pyrazinamide-resistant tuberculosis in China. Antimicrob Agents Chemother. 2016;60(9):5159–5166. doi:10.1128/AAC.02687-1527297481
   PubMed Web of Science ®Google Scholar
• Zheng X, Ning Z, Drobniewski F, et al. pncA mutations are associated with slower sputum conversion during standard treatment of multidrug-resistant tuberculosis. Int J Antimicrob Agents. 2017;49(2):183–188. doi:10.1016/j.ijantimicag.2016.10.01228012685
   PubMed Web of Science ®Google Scholar
• Spinato J, Boivin E, Belanger-Trudelle E, Fauchon H, Tremblay C, Soualhine H. Genotypic characterization of drug resistant Mycobacterium tuberculosis in Quebec, 2002-2012. BMC Microbiol. 2016;16(1):164. doi:10.1186/s12866-016-0786-427459848
   PubMed Web of Science ®Google Scholar
• Khan MT, Malik SI, Ali S, et al. Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan. BMC Infect Dis. 2019;19(1):116. doi:10.1186/s12879-019-3764-230728001
   PubMed Web of Science ®Google Scholar
• Sheen P, Lozano K, Gilman RH, et al. pncA gene expression and prediction factors on pyrazinamide resistance in Mycobacterium tuberculosis. Tuberculosis. 2013;93(5):515–522. doi:10.1016/j.tube.2013.03.00523867321
   PubMed Web of Science ®Google Scholar
• Filipenko ML, Dymova MA, Cherednichenko AG, Khrapov EA, Mishukova OV, Schwartz YS. Detection of Mutations in Mycobacterium tuberculosis pncA gene by modified high-resolution melting curve analysis of PCR products. Bull Exp Biol Med. 2019;168(2):264–269. doi:10.1007/s10517-019-04688-631782002
   PubMed Web of Science ®Google Scholar
• Rodrigues Vde F, Telles MA, Ribeiro MO, Cafrune PI, Rossetti ML, Zaha A. Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis in Brazil. Antimicrob Agents Chemother. 2005;49(1):444–446. doi:10.1128/AAC.49.1.444-446.200515616332
   PubMed Web of Science ®Google Scholar
• Rahman A, Ferdous SS, Ahmed S, et al. Pyrazinamide susceptibility and pncA mutation profiles of mycobacterium tuberculosis among multidrug-resistant tuberculosis patients in Bangladesh. Antimicrob Agents Chemother. 2017;61:9. doi:10.1128/AAC.00511-17
   Web of Science ®Google Scholar
• Alexander DC, Ma JH, Guthrie JL, Blair J, Chedore P, Jamieson FB. Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA. J Clin Microbiol. 2012;50(11):3726–3728. doi:10.1128/JCM.00620-1222895038
   PubMed Web of Science ®Google Scholar
• Tan Y, Hu Z, Zhang T, et al. Role of pncA and rpsA gene sequencing in detection of pyrazinamide resistance in Mycobacterium tuberculosis isolates from southern China. J Clin Microbiol. 2014;52(1):291–297. doi:10.1128/JCM.01903-1324131688
   PubMed Web of Science ®Google Scholar
• Khan MT, Malik SI, Bhatti AI, et al. Pyrazinamide-resistant mycobacterium tuberculosis isolates from Khyber Pakhtunkhwa and rpsA mutations. J Biol Regul Homeost Agents. 2018;32(3):705–709.29921403
   PubMed Web of Science ®Google Scholar